PFO
IRMD icon

Pathstone Family Office’s iRadimed IRMD Stock Holding History

Pathstone Family Office’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-988
Closed -$21K – 669
2019
Q2 		$21K Hold
988
– – ﹤0.01% 437
2019
Q1 		$28K Hold
988
– – ﹤0.01% 392
2018
Q4 		$25K Buy
+988
New +$26.5K 0.01% 247

Other funds holding IRMD

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
CCM
Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Pathstone Family Office's IRMD Position: Q3 2019 in Review

Pathstone Family Office sold out of iRadimed (IRMD) in Q3 2019, closing a stake of 988 shares — an estimated $21K sold.

Pathstone Family Office first reported a position in IRMD in Q4 2018 and held it in 3 quarters. The position peaked at $28K in Q1 2019. 59 funds tracked by Wall St. Rank hold IRMD as of Q3 2019.

  • Pathstone Family Office reported no remaining iRadimed position as of Q3 2019 after selling out during the quarter.
  • Pathstone Family Office sold 988 iRadimed shares in Q3 2019, an estimated $21K.
  • Pathstone Family Office first reported a position in iRadimed in Q4 2018 and held it in 3 quarters.
  • Pathstone Family Office's iRadimed position peaked at $28K in Q1 2019.
  • 59 funds tracked by Wall St. Rank held iRadimed as of Q3 2019.

Based on Pathstone Family Office's 13F filing for Q3 2019, filed 13 Nov 2019.